New two-drug combo aims to control rare lymphoma
NCT ID NCT06647732
Summary
This study is testing whether combining two existing drugs—zanubrutinib and rituximab—works better as a first treatment for MALT lymphoma, a type of slow-growing cancer that often starts in the stomach or other organs. Researchers will give the drug combination to 42 newly diagnosed patients and measure how many achieve complete remission. The goal is to find a more effective treatment that controls the disease with manageable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 51000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.